148 related articles for article (PubMed ID: 23338975)
1. Nateglinide in combination with metformin in Chinese patients with type 2 diabetes mellitus: a post-marketing surveillance study.
Yang JK; Wang L;
Clin Drug Investig; 2013 Mar; 33(3):185-91. PubMed ID: 23338975
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
Horton ES; Foley JE; Shen SG; Baron MA
Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
[TBL] [Abstract][Full Text] [Related]
3. Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84.
Weaver JU; Robertson D; Atkin SL
Diabetes Obes Metab; 2004 Sep; 6(5):344-52. PubMed ID: 15287927
[TBL] [Abstract][Full Text] [Related]
4. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
Marre M; Van Gaal L; Usadel KH; Ball M; Whatmough I; Guitard C
Diabetes Obes Metab; 2002 May; 4(3):177-86. PubMed ID: 12047396
[TBL] [Abstract][Full Text] [Related]
5. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Hirschberg Y; Karara AH; Pietri AO; McLeod JF
Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
[TBL] [Abstract][Full Text] [Related]
6. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Horton ES; Clinkingbeard C; Gatlin M; Foley J; Mallows S; Shen S
Diabetes Care; 2000 Nov; 23(11):1660-5. PubMed ID: 11092289
[TBL] [Abstract][Full Text] [Related]
7. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
[TBL] [Abstract][Full Text] [Related]
8. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
9. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
Ristic S; Collober-Maugeais C; Cressier F; Tang P; Pecher E
Diabetes Obes Metab; 2007 Jul; 9(4):506-11. PubMed ID: 17587393
[TBL] [Abstract][Full Text] [Related]
10. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.
Schwarz SL; Gerich JE; Marcellari A; Jean-Louis L; Purkayastha D; Baron MA
Diabetes Obes Metab; 2008 Aug; 10(8):652-60. PubMed ID: 17941876
[TBL] [Abstract][Full Text] [Related]
11. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Ristic S; Collober-Maugeais C; Pecher E; Cressier F
Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
[TBL] [Abstract][Full Text] [Related]
12. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.
Gerich J; Raskin P; Jean-Louis L; Purkayastha D; Baron MA
Diabetes Care; 2005 Sep; 28(9):2093-9. PubMed ID: 16123472
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
Schatz H; Schoppel K; Lehwalder D; Schandry R
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):262-6. PubMed ID: 12951631
[TBL] [Abstract][Full Text] [Related]
14. Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes.
Juurinen L; Tiikkainen M; Saltevo J; Nikkilä K; Lanki H; Leppävuori E; Kock T; Teikari-Myyrä T; Kauppinen-Mäkelin R; Kotronen A; Yki-Järvinen H
Diabet Med; 2009 Apr; 26(4):409-15. PubMed ID: 19388972
[TBL] [Abstract][Full Text] [Related]
15. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Hanefeld M; Bouter KP; Dickinson S; Guitard C
Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
[TBL] [Abstract][Full Text] [Related]
16. Study of nateglinide in Japan: long-term treatment of patients with type 2 diabetes.
Taki H; Maki T; Iso T; Iwamoto K; Kajiura T
Adv Ther; 2006; 23(2):307-24. PubMed ID: 16751163
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of nateglinide in the treatment of type II diabetes mellitus.
Chandrasekharan S; Rao PP; Jayaram S; Jain SD; Ganesan R; Desai A
J Indian Med Assoc; 2002 Jul; 100(7):467-8. PubMed ID: 12674176
[TBL] [Abstract][Full Text] [Related]
19. Meglitinide analogues for type 2 diabetes mellitus.
Black C; Donnelly P; McIntyre L; Royle PL; Shepherd JP; Thomas S
Cochrane Database Syst Rev; 2007 Apr; 2007(2):CD004654. PubMed ID: 17443551
[TBL] [Abstract][Full Text] [Related]
20. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
Salas M; Ward A; Caro J
Clin Ther; 2002 Oct; 24(10):1690-705. PubMed ID: 12462297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
